Virtual Library

Start Your Search

M. Haggag



Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      32P - Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non-small cell lung cancer (ID 262)

      12:30 - 13:00  |  Author(s): M. Haggag

      • Abstract
      • Slides

      Background:
      Cell-free DNA (ccf-DNA) can be found in healthy persons, persons with malignant and nonmalignant diseases as Chronic Obstructive Pulmonary Disease. In cancer, ccf-DNA results from tumor necrosis, lysis of circulating cancer cells or of micro-metastases and active release. Recently the first liquid biopsy test for analysis of driver gene mutation from cfDNA becomes a reality in clinical practice for patients with NSCLC with use of peripheral blood sample for EGFR mutation detection as predictive marker of response to EGFR-targeted therapy. The aim of this study was to study the concentrations and integrity index of ccf-DNA as a diagnostic and prognostic marker.

      Methods:
      This study was carried out in Menoufia University hospital in the period from October 2015 to September 2017. It was conducted on 140 individuals classified into: Group I: included 60 patients with NSCLC, Group II: included 40 patients with COPD. Group III: included 40 healthy controls. For NSCLC patients Staging was done according to the American Joint Committee on Cancer: the 7th edition. Real-time ALU-qPCR used to assess the concentration and integrity index of serum ccf-DNA.

      Results:
      The mean age was (56.8 ± 9.8, 52.9 ± 11.1 & 53.7 ± 9.0) for the three studied groups respectively with non significant difference between them. NSCLC patients demonstrated significantly higher values of each of ALU 215, ALU 247, DNA integrity than both COPD patients and controls, with non significant difference between the last two groups. The ROC curve analysis demonstrated that the total accuracy of ALU 247 was 92.1% at a cutoff point 325, 0.98 AUC, 96.7% sensitivity, 88.7% specificity, 86.6% PPV& 97.3% NPV, while ALU 115 recorded (0.93, 90%,78.7%, 76.1, 91.3 & 83.6) for AUC, sensitivity, specificity, PPV, NPV and accuracy respectively at a cutoff point 565. It was noticed that DNA integrity has AUC 0.65, sensitivity 75%, specificity 42.5%, 49.5% PPV, 69.4% NPP and total accuracy 56.4% at a cutoff point 0.48. Among NSCLC patients, ALU 115 & ALU 247 increased significantly in advanced tumor and more elevation was noticed in metastatic patients. Overall survival of NSCLC patients in relation to ALU 247, ALU 115 & DNA integrity documented a significant relationship between low DNA integrity and better survival of those patients.

      Conclusions:
      Serum DNA concentrations may be valuable in early diagnosis and potential prognostic marker in NSCLC patients

      Clinical trial identification:


      Legal entity responsible for the study:
      Menoufia University

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.